TMO Stock Forecast & Price Target

Thermo Fisher Scientific is supported by a clear acceleration in underlying demand, with 3Q organic revenue of about 6%—its best organic growth since 2Q’21—beating expectations as Patheon grew mid-to-high teens and Analytical Instruments rose 6%, showing strength in both pharma services and high-end tools. Management’s raised FY’26 guidance to $47.7-48.2B of reported revenue and $25.13-25.43 of adjusted EPS, while maintaining roughly 4% organic growth and 80bps of adjusted operating margin expansion, reinforces confidence that profitability is improving alongside sales. The company’s resilient portfolio, improving biotech funding, stable academic/government demand, and potential AI-linked wet-lab demand create a favorable setup for better-than-peer revenue and EPS growth.

Thermo Fisher Scientific is facing a weaker fundamental setup because investors have waited years for demand normalization in scientific lab supply, and management’s 2026 organic sales growth guidance of roughly 3% to 4% remains far below the long-term 7% target, making a full recovery look uncertain. Its historical M&A playbook may be less effective now as actionable targets in life science tools and reagents have become scarcer, while expanded exposure to pharma services and CRO activities may not command the same valuation premium as past consolidation wins. The stock also carries meaningful AI-related risk, with about 20% of sales tied to clinical research and roughly 40% to core scientific research supply, both vulnerable to automation and the wet lab versus dry lab shift.